Dr. Saliba and Dr. Wazni discuss the challenges of patients who would like to stop anticoagulation after atrial fibrillation ablation. The OPTION study is a research trial looking at the safety and effectiveness of the WATCHMAN device used for left atrial appendage closure vs. oral anticoagulants in patients with non valvular atrial fibrillation. Patients who have had an ablation or who are going to have an ablation will be randomized to WATCHMAN vs. oral anticoagulation. Patients will be followed for 3 years, looking at risk of stroke, mortality, cardiovascular events and risk of bleeding. Interested providers can learn more about the OPTION trial at https://clinicaltrials.gov/ct2/show/NCT03795298 or contact the Atrial Fibrillation Stroke Prevention Center https://my.clevelandclinic.org/departments/heart/depts/atrial-fibrillation-center Dr. Oussama Wazni - https://my.clevelandclinic.org/staff/7336-oussama-wazni Dr. Walid Saliba - https://my.clevelandclinic.org/staff/3456-walid-saliba